Literature DB >> 9061841

Cohort versus cross-sectional design in large field trials: precision, sample size, and a unifying model.

H A Feldman1, S M McKinlay.   

Abstract

In planning large longitudinal field trials, one is often faced with a choice between a cohort design and a cross-sectional design, with attendant issues of precision, sample size, and bias. To provide a practical method for assessing these trade-offs quantitatively, we present a unifying statistical model that embraces both designs as special cases. The model takes account of continuous and discrete endpoints, site differences, and random cluster and subject effects of both a time-invariant and a time-varying nature. We provide a comprehensive design equation, relating sample size to precision for cohort and cross-sectional designs, and show that the follow-up cost and selection bias attending a cohort design may outweigh any theoretical advantage in precision. We provide formulae for the minimum number of clusters and subjects. We relate this model to the recently published prevalence model for COMMIT, a multi-site trial of smoking cessation programmes. Finally, we tabulate parameter estimates for some physiological endpoints from recent community-based heart-disease prevention trials, work an example, and discuss the need for compiling such estimates as a basis for informed design of future field trials.

Entities:  

Mesh:

Year:  1994        PMID: 9061841     DOI: 10.1002/sim.4780130108

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

Review 1.  Methods in health service research. Evaluation of health interventions at area and organisation level.

Authors:  O C Ukoumunne; M C Gulliford; S Chinn; J A Sterne; P G Burney; A Donner
Journal:  BMJ       Date:  1999-08-07

Review 2.  A tale of 3 tails.

Authors:  J B McKinlay; L D Marceau
Journal:  Am J Public Health       Date:  1999-03       Impact factor: 9.308

3.  A comparison of the statistical power of different methods for the analysis of repeated cross-sectional cluster randomization trials with binary outcomes.

Authors:  Peter C Austin
Journal:  Int J Biostat       Date:  2010-03-29       Impact factor: 0.968

4.  Outcomes of a randomized community-level HIV prevention intervention for women living in 18 low-income housing developments.

Authors:  K J Sikkema; J A Kelly; R A Winett; L J Solomon; V A Cargill; R A Roffman; T L McAuliffe; T G Heckman; E A Anderson; D A Wagstaff; A D Norman; M J Perry; D A Crumble; M B Mercer
Journal:  Am J Public Health       Date:  2000-01       Impact factor: 9.308

5.  The importance and role of intracluster correlations in planning cluster trials.

Authors:  John S Preisser; Beth A Reboussin; Eun-Young Song; Mark Wolfson
Journal:  Epidemiology       Date:  2007-09       Impact factor: 4.822

6.  Results of the TeachWell worksite wellness program.

Authors:  K Resnicow; M Davis; M Smith; T Baranowski; L S Lin; J Baranowski; C Doyle; D T Wang
Journal:  Am J Public Health       Date:  1998-02       Impact factor: 9.308

7.  Design of the Trial of Activity in Adolescent Girls (TAAG).

Authors:  June Stevens; David M Murray; Diane J Catellier; Peter J Hannan; Leslie A Lytle; John P Elder; Deborah R Young; Denise G Simons-Morton; Larry S Webber
Journal:  Contemp Clin Trials       Date:  2005-04       Impact factor: 2.226

8.  Twenty Years of Neighborhood Effect Research: An Assessment.

Authors:  J Michael Oakes; Kate E Andrade; Ifrah M Biyoow; Logan T Cowan
Journal:  Curr Epidemiol Rep       Date:  2015-01-16

Review 9.  Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993.

Authors:  J M Simpson; N Klar; A Donnor
Journal:  Am J Public Health       Date:  1995-10       Impact factor: 9.308

10.  Sample size requirements to detect an intervention by time interaction in longitudinal cluster randomized clinical trials with random slopes.

Authors:  Moonseong Heo; Xiaonan Xue; Mimi Y Kim
Journal:  Comput Stat Data Anal       Date:  2013-04-01       Impact factor: 1.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.